Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
Academic ArticleArticle
Overview
MeSH Major
Chickenpox Vaccine
HIV Infections
Measles-Mumps-Rubella Vaccine
Mumps
Rubella
Vaccination
abstract
In treatment-experienced patients with NNRTI resistance, treatment with TMC125 achieved better virological suppression at week 24 than did placebo. The safety and tolerability profile of TMC125 was generally comparable with placebo.